These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613 [TBL] [Abstract][Full Text] [Related]
27. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722 [TBL] [Abstract][Full Text] [Related]
28. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728 [TBL] [Abstract][Full Text] [Related]
29. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170 [TBL] [Abstract][Full Text] [Related]
30. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207 [TBL] [Abstract][Full Text] [Related]
31. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978 [TBL] [Abstract][Full Text] [Related]
32. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822 [TBL] [Abstract][Full Text] [Related]
33. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells. Hirashita Y; Tsukamoto Y; Kudo Y; Kakisako D; Kurogi S; Hijiya N; Nakada C; Uchida T; Hirashita T; Hiratsuka T; Akagi T; Ueda Y; Shiroshita H; Etoh T; Mizukami K; Honda K; Okimoto T; Kodama M; Inomata M; Moriyama M; Murakami K Lab Invest; 2021 Aug; 101(8):1036-1047. PubMed ID: 33911189 [TBL] [Abstract][Full Text] [Related]
34. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409 [TBL] [Abstract][Full Text] [Related]
35. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159 [TBL] [Abstract][Full Text] [Related]
36. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. Zhou X; Zhu A; Gu X; Xie G Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663 [TBL] [Abstract][Full Text] [Related]
38. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089 [TBL] [Abstract][Full Text] [Related]
39. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711 [No Abstract] [Full Text] [Related]
40. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]